3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
51
Sarcoma
8
Gastrointestinal
5
Breast
5
Genitourinary
3
Thoracic
2
Endocrine
2
Other solid neoplasm
1
Dermatologic
1
CNS
1
Conditions
Mesothelioma, Malignant
7
Unspecified Adult Solid Tumor, Protocol Specific
5
Retinoblastoma
3
Solid Tumors
2
Sarcoma
2
Mesothelioma
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Solid Tumours
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma
1
Retinal Neoplasms
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Pheochromocytoma
1
Peritoneal Neoplasms
1
Pelvic Neoplasms
1
Ovarian Neoplasms
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Liposarcoma
1
Head and Neck Neoplasms
1
HER2-negative Breast Cancer
1
Interventions
pembrolizumab
8
fludarabine
4
Cyclophosphamide
4
amatuximab
3
Thiotepa
3
Nivolumab
3
Ipilimumab
3
Hyperthermic Intraperitoneal Chemotherapy
3
Filgrastim
3
Carboplatin
3
budigalimab
2
belinostat
2
SS1(dsFv)PE38
2
Platinum
2
Peripheral Blood Stem Cell Transplantation
2
Cisplatin
2
1,2-diaminocyclohexaneplatinum II citrate
2
venetoclax
1
talazoparib
1
sodium thiosulfate
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
epacadostat
1
durvalumab
1
bosutinib
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Doxorubicin
×
Other solid neoplasm
×
Clear all
NCT04213794
2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1
Terminated
2 enrolled